You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • AB0374 Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease: Analysis of Data Pooled from the RAPID1 and RAPID2 Randomized Trials

Article info

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Abstracts accepted for publication. Rheumatoid arthritis - anti-TNF therapy
AB0374 Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease: Analysis of Data Pooled from the RAPID1 and RAPID2 Randomized Trials

Authors

Citation

Haraoui B, Bykerk V, van Vollenhoven R, et al
AB0374 Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease: Analysis of Data Pooled from the RAPID1 and RAPID2 Randomized Trials
Annals of the Rheumatic Diseases 2014;73:929.

Publication history

  • First published June 10, 2014.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions